Blockade of D2 receptors in which dopamine pathway is responsible for the therapeutic reduction of positive psychotic symptoms?
Choose an answer, then check it.
Clinical Pharmacology · Antipsychotics and Mood Stabilizers
First-Generation Antipsychotics
On this page 6 sections
In 30 seconds
First-generation (typical) antipsychotics treat psychosis primarily by blocking dopamine D2 receptors throughout the brain. That single mechanism explains both their benefit and nearly all of their downside: blocking D2 receptors where you want to (the mesolimbic pathway) calms hallucinations and delusions, while blocking D2 receptors everywhere else causes movement disorders, hormonal changes, and worsened negative symptoms. High-potency agents like haloperidol and fluphenazine cause more movement side effects; low-potency agents like chlorpromazine and thioridazine cause more sedation, hypotension, and anticholinergic effects. Understanding the four dopamine pathways is the key to predicting every effect this drug class produces.
The college version
Mechanism: One Receptor, Four Pathways
All first-generation antipsychotics (FGAs), also called typical antipsychotics or neuroleptics, work primarily by antagonizing D2 dopamine receptors. The brain has four major dopamine pathways, and D2 blockade affects each differently:
- Mesolimbic pathway: overactive dopamine here drives the positive symptoms of psychosis (hallucinations, delusions, disorganized thought). Blocking D2 receptors here is the therapeutic goal.
- Mesocortical pathway: dopamine here is already thought to be underactive in schizophrenia, contributing to negative symptoms (flat affect, social withdrawal, avolition) and cognitive deficits. Further D2 blockade can worsen these symptoms, which is a major limitation of FGAs.
- Nigrostriatal pathway: dopamine here regulates voluntary movement. Blockade produces extrapyramidal symptoms (EPS) — acute dystonia, akathisia, parkinsonism, and with long-term use, tardive dyskinesia. (The sibling topic on movement disorders covers these in depth; the key point here is that EPS risk tracks directly with D2 affinity.)
- Tuberoinfundibular pathway: dopamine normally inhibits prolactin release from the pituitary. Blockade removes that brake, causing hyperprolactinemia — galactorrhea, gynecomastia, menstrual irregularities, and sexual dysfunction.
Because FGAs block D2 receptors non-selectively across all four pathways, therapeutic benefit in one pathway is inseparable from adverse effects in the other three. This is the central conceptual difference from second-generation antipsychotics, which modulate serotonin alongside dopamine and produce comparatively less EPS.
Potency Spectrum: High-Potency vs. Low-Potency
FGAs exist on a potency spectrum based on D2 receptor affinity, and potency predicts the side-effect profile:
- High-potency agents (haloperidol, fluphenazine) bind D2 receptors tightly at low doses. They cause pronounced EPS and hyperprolactinemia but relatively little sedation, hypotension, or anticholinergic effect, because they have weak affinity for histamine, alpha-1 adrenergic, and muscarinic receptors.
- Low-potency agents (chlorpromazine, thioridazine) require higher doses to achieve the same D2 blockade, but they also bind histamine H1 receptors (sedation), alpha-1 receptors (orthostatic hypotension), and muscarinic receptors (dry mouth, blurred vision, constipation, urinary retention). This gives them less EPS but more of these other adverse effects.
This inverse relationship — EPS risk versus anticholinergic/sedating/hypotensive risk — is one of the most testable concepts in this drug class.
Indications
FGAs are approved and used for schizophrenia and other psychotic disorders, acute agitation (including in emergency and inpatient settings), Tourette syndrome (tic suppression, notably with haloperidol), and, at low doses, intractable hiccups and refractory nausea/vomiting (chlorpromazine and related agents have antiemetic activity via D2 blockade in the chemoreceptor trigger zone).
Long-Acting Injectable Formulations
Haloperidol decanoate and fluphenazine decanoate are available as long-acting injectables (LAIs), administered on a multi-week schedule. LAIs improve adherence in patients with chronic psychotic illness who struggle with daily oral regimens, reducing relapse and rehospitalization by removing the day-to-day decision to take medication.
Major Adverse Effects
Beyond EPS and hyperprolactinemia, clinically important adverse effects include:
- QT prolongation: several FGAs, especially thioridazine and intravenous haloperidol, prolong the QT interval and carry risk of torsades de pointes; this requires caution with other QT-prolonging drugs and in patients with cardiac risk factors.
- Photosensitivity: chlorpromazine in particular increases sun sensitivity and can cause exaggerated sunburn or skin discoloration.
- Lowered seizure threshold: FGAs, especially low-potency agents, lower the seizure threshold and warrant caution in patients with seizure disorders.
- Neuroleptic malignant syndrome (NMS): a rare but life-threatening reaction marked by high fever, severe muscle rigidity, autonomic instability, and altered mental status, resulting from abrupt, severe central dopamine blockade. It is a medical emergency requiring drug discontinuation and supportive care.
Boxed Warning
All antipsychotics, including FGAs, carry a boxed warning against use in older adults with dementia-related psychosis, reflecting an increased risk of death (largely cardiovascular and infectious) observed in this population. FGAs are not approved for this use, and clinicians must weigh risks carefully when off-label use is considered.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine your brain has one important chemical messenger called dopamine, and it travels along four different roads to four different neighborhoods. One neighborhood is causing trouble (that's the psychosis), so the medicine puts up a roadblock to calm it down. But the medicine can't just block that one road — it puts up roadblocks on all four roads at once.
Road 1 (the trouble neighborhood): blocking it helps, and the person feels less confused and stops hearing or seeing things that aren't there. Road 2 (a neighborhood that was already a little too quiet): blocking it more makes that neighborhood even quieter, which can make the person seem more withdrawn. Road 3 (the neighborhood in charge of smooth movement): blocking it makes muscles stiff, shaky, or restless. Road 4 (the neighborhood in charge of a hormone called prolactin): blocking it lets that hormone rise too high, causing body changes.
Some medicines (like haloperidol) are very strong at blocking roads and mostly cause the road 3 and road 4 problems. Other medicines (like chlorpromazine) are weaker at blocking roads but bump into other systems on the way, causing sleepiness, dizzy standing-up spells, and dry mouth instead. It's a trade-off: you can't get the good effect on Road 1 without some side effect on the other three roads.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with chronic schizophrenia has been repeatedly hospitalized because she stops taking her daily oral medication once she feels better. What FGA formulation strategy could address this specific problem, and why?
Show answer
Long-acting injectable (LAI) formulation
A long-acting injectable form of an FGA, like haloperidol decanoate or fluphenazine decanoate, given every few weeks, removes the need for daily pill-taking and directly addresses adherence problems that lead to relapse and rehospitalization.
An older adult with dementia is exhibiting agitation and psychotic symptoms, and a family member asks why the physician is hesitant to prescribe a first-generation antipsychotic. What should you explain?
Show answer
Boxed warning explanation
FGAs (like all antipsychotics) carry a boxed warning because studies show older adults with dementia-related psychosis who take these drugs have an increased risk of death, so the physician must weigh that serious risk carefully before using it off-label in this population.
Quick check
3 questions here. Answers stay hidden until you check.
Which of the following best describes the adverse effect profile of a low-potency first-generation antipsychotic such as chlorpromazine, compared to a high-potency agent like haloperidol?
Choose an answer, then check it.
A patient on a first-generation antipsychotic develops high fever, severe muscle rigidity, and autonomic instability. This presentation is most consistent with which condition?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.